DrugPatentWatch Database Preview
Takeda Pharms Usa Company Profile
What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?
There are eighty-one US patents protecting TAKEDA PHARMS USA drugs.
There are one thousand and fifty-four patent family members on TAKEDA PHARMS USA drugs in fifty-eight countries and ninety-eight supplementary protection certificates in fifteen countries.
Summary for Takeda Pharms Usa
| International Patents: | 1054 |
| US Patents: | 81 |
| Tradenames: | 17 |
| Ingredients: | 14 |
| NDAs: | 17 |
Drugs and US Patents for Takeda Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | 6,462,058*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-001 | Jan 25, 2013 | RX | Yes | No | 7,459,428 | ➤ Sign Up | ➤ Sign Up | ||||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | RX | Yes | No | 6,462,058*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 021428-002 | Aug 30, 2002 | AB | RX | Yes | Yes | 7,431,942*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Takeda Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-001 | Jan 25, 2013 | 6,172,090 | ➤ Sign Up |
| Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 021428-001 | Aug 30, 2002 | 5,433,959*PED | ➤ Sign Up |
| Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 021428-001 | Aug 30, 2002 | 6,749,864 | ➤ Sign Up |
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | 6,329,404 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
| ➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
| ➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
| ➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
| ➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
| ➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
| ➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
| ➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
| ➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
| ➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
| ➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
| ➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
Non-Orange Book US Patents for Takeda Pharms Usa
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,803,357 | Method of regulating glucose metabolism, and reagents related thereto | ➤ Sign Up |
| 5,965,584 | Pharmaceutical composition | ➤ Sign Up |
| 6,080,765 | Pharmaceutical composition | ➤ Sign Up |
| 6,172,090 | Pharmaceutical composition | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Takeda Pharms Usa Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Morocco | 29557 | ➤ Sign Up |
| Argentina | 046210 | ➤ Sign Up |
| Denmark | 1553929 | ➤ Sign Up |
| South Korea | 20100036367 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Takeda Pharms Usa Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C026/2009 | Ireland | ➤ Sign Up | SPC026/2009: 20101001, EXPIRES: 20210619 |
| 2014011 | Lithuania | ➤ Sign Up | PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919 |
| 2 5006-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: ALOGLIPTIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130923 |
| 2012022 | Lithuania | ➤ Sign Up | PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
